Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
- 27 September 2020
- book chapter
- Published by Springer Nature
- Vol. 179, 31-71
Abstract
Due to a tragic increase in the incidences of diabetes globally, diabetic kidney disease (DKD) has emerged as one of the leading causes of end-stage renal diseases (ESRD). Hyperglycaemia-mediated overactivation of the renin-angiotensin-aldosterone system (RAAS) is key to the development and progression of DKD. Consequently, RAAS inhibition by angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) is the first-line therapy for the clinical management of DKD. However, numerous clinical and preclinical evidences suggested that RAAS inhibition can only halt the progression of the DKD to a certain extent, and they are inadequate to cure DKD completely. Recent studies have improved understanding of the complexity of the RAAS. It consists of two counter-regulatory arms, the deleterious pressor arm (ACE/angiotensin II/AT1 receptor axis) and the beneficial depressor arm (ACE2/angiotensin-(1-7)/Mas receptor axis). These advances have paved the way for the development of new therapies targeting the RAAS for better treatment of DKD. In this review, we aimed to summarise the involvement of the depressor arm of the RAAS in DKD. Moreover, in modern drug discovery and development, an advance approach is the bispecific therapeutics, targeting two independent signalling pathways. Here, we discuss available reports of these bispecific drugs involving the RAAS as well as propose potential treatments based on neurohormonal balance as credible therapeutic strategies for DKD.Keywords
This publication has 155 references indexed in Scilit:
- Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace InhibitorPLOS ONE, 2013
- Angiotensin II Type II Receptor Deficiency Accelerates the Development of Nephropathy in Type I Diabetes via Oxidative Stress and ACE2Experimental Diabetes Research, 2011
- Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and NephropathyClinical Journal of the American Society of Nephrology, 2011
- Intratubular Renin-Angiotensin System in HypertensionHypertension, 2011
- Renal protection in diabetes: lessons from ONTARGET®Cardiovascular Diabetology, 2010
- Human Recombinant ACE2 Reduces the Progression of Diabetic NephropathyDiabetes, 2009
- Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and AlbuminuriaDiabetes Care, 2009
- Tubular and Glomerular Injury in Diabetes and the Impact of ACE InhibitionDiabetes Care, 2009
- Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysisDiabetic Medicine, 2007
- Functional adrenal zonation and regulation of aldosterone biosynthesisCurrent Opinion in Endocrinology, Diabetes and Obesity, 1998